The role of tumor microenvironment in cholangiocarcinoma

Abstract

Cholangiocarcinoma (CCA) is an extremely aggressive neoplasia, mostly because of diagnostic delay and lack of effective therapies. CCA is typically surrounded by a peculiar microenvironment that includes abundant desmoplastic stroma and various cell types, which support and enhance CCA development. Among the tumor microenvironment (TME) cells, there are tumor infiltrating lymphocytes (TILs), such as CD8⁺ and CD4⁺ cells, Tregs, natural killers (NKs) and B lymphocytes. TILs contribute to an immunosuppressive microenvironment that leads to tumor immune escape. Dendritic cells (DCs) may lead to immunotolerance by maturation or antigen-presentation deficiency. Hepatic stellate cells (HSCs) are one of the major precursors of cancer-associated fibroblast (CAFs), which are distinguished in various subpopulations, each with different functions and interactions with other TME cells. CAFs can promote lymphangiogenesis, early lymph-node metastasis and proinflammatory environment, but they can also provide a physical and chemical barrier to protect CCA. Tumor-associated macrophages (TAMs) could be differentiated between two phenotypes, pro- and anti-inflammatory, and they may sustain invasiveness and immunosuppression. Myeloid-derived suppressor cells (MDSCs) impair cytotoxic T lymphocytes (CTLs) function, stimulating tumor proliferation and angiogenesis. Tumor-associated neutrophils (TANs) function is influenced by the TME, leading to tumor-suppressing or tumor-promoting functions. This paper aims to provide an overview of the CCA microenvironment cells, their role in tumor progression and possible correlated diagnostic, therapeutic and prognostic implications.

Keywords

Tumor microenvironments / cholangiocarcinoma / cancer-associated fibroblast / tumor‐associated macrophages / myeloid-derived suppressor cells / Tumor-infiltrating lymphocytes / dendritic cells / immunotherapy

References

[1] Labib PL,Pereira SP.Molecular pathogenesis of cholangiocarcinoma.BMC Cancer2019;19:185 PMCID:PMC6394015

[2] Goeppert B,Zucknick M.Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer.Br J Cancer2013;109:2665-74 PMCID:PMC3833207

[3] Zhou G,Mancham S.Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.J Hepatol2019;71:753-62

[4] Fabris L,Mertens J.The tumour microenvironment and immune milieu of cholangiocarcinoma.Liver Int2019;39 Suppl 1:63-78

[5] Zhou SL,Zhou ZJ.CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils.Carcinogenesis2014;35:597-605

[6] Yang X,Shi Y.FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling.Cancer Res2016;76:4124-35

[7] Veglia F.Dendritic cells in cancer: the role revisited.Curr Opin Immunol2017;45:43-51 PMCID:PMC5449252

[8] Zou W.Immunosuppressive networks in the tumour environment and their therapeutic relevance.Nat Rev Cancer2005;5:263-74

[9] Miura T,Hirai H.Prognostic impact of CD163⁺ macrophages in tumor stroma and CD8⁺ T-Cells in cancer cell nests in invasive extrahepatic bile duct cancer.Anticancer Res2017;37:183-90

[10] Chariyalertsak S,Mayer D.Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.Gut2001;48:80-6 PMCID:PMC1728157

[11] Sirica AE,Zhang Z.Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.J Gastroenterol Hepatol2001;16:363-72

[12] Endo K,Pairojkul C,Sirica AE.ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.Hepatology2002;36:439-50

[13] Hayashi N,Hiraoka N.Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.Hepatology2001;34:638-50

[14] Joyce JA.T cell exclusion, immune privilege, and the tumor microenvironment.Science2015;348:74-80

[15] Liu D,Czigany Z.The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.J Exp Clin Cancer Res2022;41:127 PMCID:PMC8988317

[16] Carnevale G,Cardinale V.Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells.Sci Rep2017;7:14419 PMCID:PMC5663931

[17] Duan SG,Li DJ.The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells.Dig Dis Sci2010;55:2844-52

[18] Parham P.Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution.Nat Rev Immunol2013;13:133-44 PMCID:PMC3956658

[19] Cornillet M,Schaffer M.Imbalance of genes encoding natural killer immunoglobulin-like receptors and human leukocyte antigen in patients with biliary cancer.Gastroenterology2019;157:1067-1080.e9

[20] Kim HD,Park S.Implication of CD69⁺ CD103⁺ tissue-resident-like CD8⁺ T cells as a potential immunotherapeutic target for cholangiocarcinoma.Liver Int2021;41:764-76

[21] Ye Y,Xie X,Xie H.Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.J Surg Oncol2009;100:500-4

[22] Qian Y,Yang T.aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.Hepatology2017;66:1165-82

[23] Labani-Motlagh A,Loskog A.The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses.Front Immunol2020;11:940 PMCID:PMC7243284

[24] Tormoen GW,Gough MJ.Role of the immunosuppressive microenvironment in immunotherapy.Adv Radiat Oncol2018;3:520-6 PMCID:PMC6200899

[25] Diggs LP,Ma C.CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.J Hepatol2021;74:1145-54 PMCID:PMC9662232

[26] Pan YR,Chen MH.Comprehensive evaluation of immune-checkpoint dna cancer vaccines in a rat cholangiocarcinoma model.Vaccines (Basel)2020;8:703 PMCID:PMC7712087

[27] Sawasdee N,Sujjitjoon J.Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.Int Immunopharmacol2020;78:106006

[28] Morisaki T,Kiyota A.Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.Anticancer Res2012,32:2249-56

[29] Yoon JG,Jang M.Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses.Hepatology2021;74:1914-31

[30] Le DT,Smith KN.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[31] Goeppert B,Renner M.Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.Br J Cancer2019;120:109-14 PMCID:PMC6325153

[32] Spizzo G,Xiu J.Molecular profile of BRCA-mutated biliary tract cancers.ESMO Open2020;5:e000682 PMCID:PMC7312328

[33] Rizzo A,Brandi G.Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.Expert Opin Investig Drugs2021;30:343-50

[34] Asahi Y,Hatanaka Y.Prognostic impact of CD8⁺ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma.Surg Today2020;50:931-40

[35] Tian L,Ma L.PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.World J Surg Oncol2020;18:303 PMCID:PMC7686719

[36] Wu H,Jian M.Clinicopathological and prognostic significance of immunoscore and PD-L1 in intrahepatic cholangiocarcinoma.Onco Targets Ther2021;14:39-51 PMCID:PMC7797318

[37] Xu YP,Zhao YJ.High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma.J Cancer2021;12:4655-60 PMCID:PMC8210563

[38] Lu JC,Sun QM.Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors.Theranostics2019;9:4678-87 PMCID:PMC6643449

[39] Ueno T,Hatanaka KC.Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma.Oncotarget2018;9:20034-47 PMCID:PMC5929444

[40] Kasper HU,Stippel DL,Gillessen A.Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma.World J Gastroenterol2009;15:5053-7 PMCID:PMC2768884

[41] Alvisi G,Soldani C.Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.J Hepatol2022;77:1359-72

[42] Vigano L,Franceschini B.Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular carcinoma. impact on prognosis after complete surgery.J Gastrointest Surg2019;23:2216-24

[43] Kim HD,Ryu YM.Spatial distribution and prognostic implications of tumor-infiltrating FoxP3- CD4⁺ T cells in biliary tract cancer.Cancer Res Treat2021;53:162-71 PMCID:PMC7812013

[44] Hasita H,Okabe H.Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.Cancer Sci2010;101:1913-9

[45] Kitano Y,Yamashita YI.Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.Br J Cancer2018;118:171-80 PMCID:PMC5785749

[46] Oshikiri T,Shichinohe T.Prognostic value of intratumoral CD8⁺ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response.J Surg Oncol2003;84:224-8

[47] Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes.Nat Rev Immunol2003;3:867-78

[48] Cheng JT,Yi HM.Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation.Oncogenesis2016;5:e198 PMCID:PMC5154347

[49] Martín-Sierra C,Laranjeira P.Functional impairment of circulating FcεRI⁺ monocytes and myeloid dendritic cells in hepatocellular carcinoma and cholangiocarcinoma patients.Cytometry B Clin Cytom2019;96:490-5

[50] Paillet J,Pol JG.Immune contexture of cholangiocarcinoma.Curr Opin Gastroenterol2020;36:70-6

[51] Jiraviriyakul A,Kaewthet P,Bayan P.Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.World J Gastroenterol2019;25:3941-55 PMCID:PMC6689815

[52] Changkija B, Konwar R. Role of interleukin-10 in breast cancer.Breast Cancer Res Treat2012;133:11-21

[53] Landskron G,Thuwajit P,Hermoso MA.Chronic inflammation and cytokines in the tumor microenvironment.J Immunol Res2014;2014:149185 PMCID:PMC4036716

[54] Thepmalee C,Junking M,Yenchitsomanus PT.Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.Hum Vaccin Immunother2018;14:1423-31 PMCID:PMC6037468

[55] Shimizu K,Aruga A,Takasaki K.Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.J Hepatobiliary Pancreat Sci2012;19:171-8

[56] Panya A,Sawasdee N.Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.Cancer Immunol Immunother2018;67:1579-88

[57] Hu ZQ,Luo CB.Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection.Cancer Cell Int2020;20:582 PMCID:PMC7716503

[58] Takagi S,Ichikawa E.Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma.Hum Pathol2004;35:881-6

[59] Okabe H,Hayashi H.Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.Ann Surg Oncol2009;16:2555-64

[60] Dranoff JA.Portal fibroblasts: underappreciated mediators of biliary fibrosis.Hepatology2010;51:1438-44 PMCID:PMC2850946

[61] Shimoda M,Orimo A.Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression.Semin Cell Dev Biol2010;21:19-25 PMCID:PMC2828545

[62] Franco OE,Strand DW.Cancer associated fibroblasts in cancer pathogenesis.Semin Cell Dev Biol2010;21:33-9 PMCID:PMC2823834

[63] Zhang M,Wan L.Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.J Hepatol2020;73:1118-30

[64] Affo S,Brundu F.Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.Cancer Cell2021;39:883 PMCID:PMC8241235

[65] Sirica AE.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.Nat Rev Gastroenterol Hepatol2011;9:44-54

[66] Sirica AE,Dumur CI.Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma.Curr Opin Gastroenterol2011;27:276-84

[67] Brivio S,Strazzabosco M.Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness.World J Hepatol2017;9:455-68 PMCID:PMC5368623

[68] Cadamuro M,Mertens J.Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.J Hepatol2019;70:700-9

[69] Sirica AE.Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting.Hepatology2014;59:2397-402 PMCID:PMC3975806

[70] Erez N,Olson P,Hanahan D.Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner.Cancer Cell2010;17:135-47

[71] Clapéron A,Aoudjehane L.Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.Hepatology2013;58:2001-11

[72] Mertens JC,Christensen JD.Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.Cancer Res2013;73:897-907 PMCID:PMC3549008

[73] Montori M,Argenziano ME.Cancer-associated fibroblasts in cholangiocarcinoma: current knowledge and possible implications for therapy.J Clin Med2022;11:6498 PMCID:PMC9654416

[74] Okamoto K,Nakanuma S.Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma.Int J Oncol2012;41:573-82

[75] Yangngam S,Pongpaibul A.High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma.J Cancer2020;11:6571-81 PMCID:PMC7545672

[76] Sha M,Qiu BJ.Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma.Cancer Med2018;7:4665-77 PMCID:PMC6144256

[77] Yamanaka T,Yokobori T.Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts.Br J Cancer2020;122:986-94 PMCID:PMC7109053

[78] Cao H,Dai M.Tumor microenvironment and its implications for antitumor immunity in cholangiocarcinoma: future perspectives for novel therapies.Int J Biol Sci2022;18:5369-90 PMCID:PMC9461676

[79] Shiraha H,Okada H.Hepatic stellate cells in liver tumor.Adv Exp Med Biol2020;1234:43-56

[80] Shi Y.Mechanisms of TGF-beta signaling from cell membrane to the nucleus.Cell2003;113:685-700

[81] Liu C,Abdelhakim H.IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver.J Clin Invest2013;123:1138-56 PMCID:PMC3582119

[82] Tu K,Verma VK.Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors.Hepatology2015;61:361-74 PMCID:PMC4262723

[83] Sun L,Wang X.PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II.Cell Rep2022;38:110349 PMCID:PMC8903892

[84] Chen Y,Tu K.Focal adhesion kinase promotes hepatic stellate cell activation by regulating plasma membrane localization of TGFβ receptor 2.Hepatol Commun2020;4:268-83 PMCID:PMC6996408

[85] Raggi C,Sica A.Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.J Hepatol2017;66:102-15 PMCID:PMC5522599

[86] Wang LX,Wu HJ,Guo J.M2b macrophage polarization and its roles in diseases.J Leukoc Biol2019;106:345-58 PMCID:PMC7379745

[87] Ruffolo LI,Kuhlers PC.GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.Gut2022;71:1386-98 PMCID:PMC8857285

[88] Zhang Y,Li J,Qian Y.Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis.World J Surg Oncol2021;19:59 PMCID:PMC7901112

[89] Thanee M,Techasen A.Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis.Asian Pac J Cancer Prev2015;16:3043-50

[90] Sun D,Dong P.M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.J Cell Biochem2020;121:2828-38

[91] Roy S,Chakraborty S.Inflammation and progression of cholangiocarcinoma: role of angiogenic and lymphangiogenic mechanisms.Front Med (Lausanne)2019;6:293 PMCID:PMC6930194

[92] Wang Q,Lan L,Xiang R.Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages.Cell Res2010;20:701-12

[93] Duluc D,Tan F.Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells.Blood2007;110:4319-30

[94] Shapouri-Moghaddam A,Vazini H.Macrophage plasticity, polarization, and function in health and disease.J Cell Physiol2018;233:6425-40

[95] Sato K,Giang T,Alpini G.Mechanisms of cholangiocyte responses to injury.Biochim Biophys Acta Mol Basis Dis2018;1864:1262-9 PMCID:PMC5742086

[96] Subimerb C,Khuntikeo N.Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma.Mol Med Rep2010;3:597-605

[97] Boulter L,Kendall TJ.WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.J Clin Invest2015;125:1269-85 PMCID:PMC4362247

[98] Loilome W,Techasen A.Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.Tumour Biol2014;35:5357-67 PMCID:PMC4862210

[99] Fabris L,Alpini G.The tumor microenvironment in cholangiocarcinoma progression.Hepatology2021;73 Suppl 1:75-85 PMCID:PMC7714713

[100] Thongchot S,Loilome W.High expression of HIF-1α, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis.Asian Pac J Cancer Prev2014;15:5873-8

[101] Dwyer BJ,Gogoi-Tiwari J.TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.J Hepatol2021;74:860-72

[102] Yuan D,Berger E.Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS.Cancer Cell2017;31:771-789.e6 PMCID:PMC7909318

[103] Tu J,Chen L.Long non-coding RNA PCAT6 induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway.Front Oncol2020;10:605877 PMCID:PMC7859434

[104] Chen S,Li Z.Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256.Cell Death Dis2022;13:94 PMCID:PMC8799724

[105] Luo C,Zhou Z.Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.Hepatology2022;76:982-99

[106] Veglia F,Gabrilovich D.Myeloid-derived suppressor cells coming of age.Nat Immunol2018;19:108-19 PMCID:PMC5854158

[107] Eggert T,Ji J.Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression.Cancer Cell2016;30:533-47 PMCID:PMC7789819

[108] Loeuillard E,Buckarma E.Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.J Clin Invest2020;130:5380-96 PMCID:PMC7524481

[109] Shaul ME.Tumour-associated neutrophils in patients with cancer.Nat Rev Clin Oncol2019;16:601-20

[110] Fridlender ZG,Kim S.Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.Cancer Cell2009;16:183-94 PMCID:PMC2754404

[111] Zhou Z,Sun R.Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3.J Immunother Cancer2021;9:e001946 PMCID:PMC7949476

[112] Gao Y,Zhou N.Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma.Nat Biomed Eng2020;4:743-53

[113] Mao ZY,Xiong M,Bai L.Prognostic value of neutrophil distribution in cholangiocarcinoma.World J Gastroenterol2015;21:4961-8 PMCID:PMC4408469

[114] Tan DW,Su Q.Prognostic significance of neutrophil to lymphocyte ratio in oncologic outcomes of cholangiocarcinoma: a meta-analysis.Sci Rep2016;6:33789 PMCID:PMC5046177

[115] Buettner S,Kimbrough CW.The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.Surgery2018;164:411-8

[116] Okabe H,Ueda M.Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts.Int J Cancer2012;131:2234-41

[117] Gentilini A,Marra F.The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium.Int J Mol Sci2018;19:2885 PMCID:PMC6213545

[118] Rimassa L,Aghemo A.The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision medicine.J Autoimmun2019;100:17-26

[119] Rompianesi G,Gordon-Weeks A,Troisi R.Liquid biopsy in cholangiocarcinoma: current status and future perspectives.World J Gastrointest Oncol2021;13:332-50 PMCID:PMC8131901

[120] Wang Y,Chen X,Xu M.The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10.Oncol Lett2016;11:1527-30 PMCID:PMC4734314

[121] Martinez VG,Salimu J.Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.Oncoimmunology2017;6:e1362530 PMCID:PMC5706614

[122] Jung HH,Lim JE.Cytokine profiling in serum-derived exosomes isolated by different methods.Sci Rep2020;10:14069 PMCID:PMC7442638